Paper Details

  1. Home
  2. Paper Details

Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.

Author: DusciLeon, GuttnerYvonne, MarshallBarry J, ViialaCharlie H, WindsorHelen M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Nitazoxanide (NTZ) was evaluated as a single agent for treating Helicobacter pylori infection. In 20 patients who had previously failed eradication therapy, NTZ failed to eradicate H. pylori. While no major adverse reactions were observed, frequent minor side effects were reported.
Paper Details　
Original Abstract of the Article :
Nitazoxanide (NTZ) is an antibiotic with microbiological characteristics similar to those of metronidazole but without an apparent problem of resistance. The aim of this study was the prospective evaluation of NTZ given as a single agent in the treatment of Helicobacter pylori infection. Twenty cult...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1128/AAC.47.12.3780-3783.2003

データ提供：米国国立医学図書館（NLM）

Nitazoxanide: A New Hope for Helicobacter pylori Infection

Helicobacter pylori, a bacterium that infects the stomach, is like a persistent desert wind, causing irritation and discomfort. This research explores the effectiveness of a drug called nitazoxanide (NTZ) in treating H. pylori infection. It's like introducing a new type of desert plant, hoping it will outcompete the harmful weeds. The researchers found that NTZ was not effective in eradicating H. pylori when used as a single agent. It's like using a simple tool to fight a powerful storm, not quite enough to conquer the challenge.

Nitazoxanide: A Promising Antibiotic with Limitations

The study found that NTZ was not effective in eradicating H. pylori when used as a single agent. It's a reminder that finding effective treatments for stubborn infections is a complex and ongoing process. It's like navigating a vast desert, searching for the right solution to a persistent problem.

Ongoing Research and Development

This research highlights the need for ongoing research and development to find effective treatments for H. pylori infection. It's like searching for a hidden oasis in the desert, tirelessly seeking a solution to a persistent challenge.

Dr.Camel's Conclusion

This study provides valuable insights into the limitations of NTZ in treating H. pylori infection. It underscores the importance of continued research to develop more effective treatments for this common and persistent infection. It's a reminder that even in the face of seemingly insurmountable challenges, scientific inquiry can pave the way for new discoveries and solutions.
Date :
  1. Date Completed 2004-01-13
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

14638482

DOI: Digital Object Identifier

10.1128/AAC.47.12.3780-3783.2003

Related Literature

Article Analysis
・Side Effects of nitazoxanide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.